Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Total Current Liabilities (2013 - 2026)

Scynexis' (SCYX) quarterly Total Current Liabilities came in at $5.8 million in Q2 2026, down 46.38% on a YoY basis from $10.9 million in Q2 2025, and down 63.36% quarter-over-quarter from $15.9 million in Q1 2026.

Analysis

Scynexis (SCYX) Total Current Liabilities (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Total Current Liabilities for 14 consecutive years, with $5.8 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Total Current Liabilities fell 46.38% year-over-year to $5.8 million; the trailing twelve-month figure through Jun 2026 stood at $5.8 million (down 46.38% YoY), and the FY2025 full-year result was $5.7 million, down 76.21% from the prior year.
  • Total Current Liabilities declined to $5.8 million in Q2 2026 per SCYX's latest filing, from $15.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $45.6 million in Q1 2023 and bottomed at $5.7 million in Q4 2025.
  • Historically, Total Current Liabilities has averaged $17.4 million across 5 years, with a median of $16.1 million in 2022.
  • The sharpest annual moves came in 2023 and 2025: Total Current Liabilities soared 252.63% in 2023, then plunged 76.21% in 2025.
  • Over 5 years, Total Current Liabilities stood at $17.6 million in 2022, then retreated by 7.46% to $16.3 million in 2023, then soared by 47.82% to $24.1 million in 2024, then slumped by 76.21% to $5.7 million in 2025, then increased by 1.59% to $5.8 million in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods registered $5.8 million, $15.9 million, and $5.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 25.50 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 11.02 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 3.94 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 5.53 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn 1.58 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 2.53 Bn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 1.51 Bn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 3.92 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 283.60 Mn
10 Scynexis 58.41 Mn -56.29 Mn - 5.83 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 5.83 Mn
Mar 31, 2026 15.90 Mn
Dec 31, 2025 5.73 Mn
Sep 30, 2025 8.47 Mn
Jun 30, 2025 10.86 Mn
Mar 31, 2025 8.96 Mn
Dec 31, 2024 24.10 Mn
Sep 30, 2024 25.72 Mn
Jun 30, 2024 25.23 Mn
Mar 31, 2024 27.35 Mn
Dec 31, 2023 16.30 Mn
Sep 30, 2023 16.79 Mn
Jun 30, 2023 16.16 Mn
Mar 31, 2023 45.64 Mn
Dec 31, 2022 17.62 Mn
Sep 30, 2022 14.26 Mn
Jun 30, 2022 16.01 Mn
Mar 31, 2022 12.94 Mn
Dec 31, 2021 13.62 Mn
Sep 30, 2021 13.22 Mn